Restructuring for Success: Shifting Biotech Strategies
During a panel discussion at Elsevier Business Intelligence’s Therapeutic Area Partnerships conference in Boston in December 2011, experienced investors and biotech executives drew lessons from difficult restructurings and successful transitions.
You may also be interested in...
The European Commission’s proposals for solving the post-Brexit regulatory problems relating to the Northern Ireland market are welcome but they do not go far enough and risk leaving suppliers in a legal limbo, says the off-patent medicines industry.
SNG001 has moved into a Phase III open label trial in which it must prove its non-inferiority against Regeneron's monoclonal antibody cocktail.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.